Back
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Opening Session and Congress Overview
Hal Broxmeyer - A Lifetime of Discovery
Hal Broxmeyer - The Consummate Mentor
The Story of the First Transplant
Hal Broxmeyer - Panel Discussion
Long-Term Outcomes including Chronic GvHD and Quality of Life
Advantages of Cord Blood Transplantation over other Sources - Japanese Registry Analysis
Secondary Malignancies after Cord Blood Transplantation
Why Choose a Cord Blood Donor? Long-Term Outcomes of Cord Blood Transplantation Q&A
Practical Challenges in Cord Blood Transplantation - How Can Registries and Cord Blood Banks Help?
The Role of Cord Blood Banks for Unrelated Stem Cell Transplantation in Japan
The UK Cord Consortium - Maximizing Patient Benefit and Securing the Future of Cord Blood Transplant
Best Practices to Address Gaps in Education about Cord Blood Utilization Q&A
Allogeneic Transplant with Omidubicel
UM 171 Expansion Strategy
Expansion Strategies to Improve Graft-vs-Leukemia
Expansion of Cord Blood Cells - New Horizons for Cord Blood Transplantation Q&A
Zika and Its Impact on Cord Blood Banking
Cord Blood for Covid-19
Manufacture of Cord Blood-Derived T-Regulatory Cells
Cord Blood as a Platform Technology - Beyond Transplant Q&A
Literature Review
Regulatory Pathways for the Development of Gene and Cell Therapies for Rare Diseases
Ask the FDA - Definitive Answers to Questions from around the World Submitted to the U.S. Food & Drug Administration
Experience of Earthquake and Tsunami
Radiation Treatment Network
Wartime Preparedness - Ukraine Cord Blood Bank
Investigations of Cord Blood in Cerebral Palsy
Development of Therapies from Cord Blood-Derived iPSC Cells
Update on Clinical Trials Evaluating Cell Therapy for Autism
Beyond Transplant - Cord Blood and Birthing Tissues as a Source of Novel Therapeutics Q&A (Supported by Macopharma)
Novel Business Models to Sustain Banks
Optimal Management of Inventory in a Public Bank
Do's and Don'ts of Growth
Mergers & Acquisitions - Opportunities & Challenges
Expanding the Portfolio of Cord Blood Banks Q&A
Anti-CD30 CAR-like Cord Blood-Derived NK Cells for CD30+ Lymphomas
Cord Blood-Derived Immune Effector Cells Q&A
Cord Blood as a Platform Technology - Introduction & Background
Preparing Cord Blood Banks for Success in New Frontiers
Leveraging CB Operations to Diversify CB Utility: Cleveland Cell Therapy Incubator
Opportunities/Challenges of Using Public Cord Blood Units for Platform Technologies
Cord Blood as a Platform Technology - Supporting Emerging Cell and Gene Therapies Q&A
Should CBU Distribution Patterns Impact Collection Strategies?
A Randomized Placebo-Controlled Phase 2 Trial of Intravenous Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke
Safety of DUOC-01, Intrathecal Cord Blood-Derived Cellular Therapy, as an Adjunct to Allogeneic Cord Blood Transplantation in Children with Inherited Metabolic Diseases
Improving HLA Barriers to Transplant Access
Non-HLA Barriers to Transplant Access
The Role of Clinical Trials in Improving Access to Transplant and to Reduce Health Care Disparity
How Cord Blood Improves Access to Transplant Care and Decreases Health Care Disparities Q&A
Optimized Transplant Practices Translate to Outstanding Survival in Adult Cord Blood Transplant Recipients
Update on Haplo Cord Transplant
Left on Tenth
Decellularized Wharton's Jelly Matrix for Regenerative Medicine and Cancer Application
-
CT
This presentation is not available, by agreement with the author.
Decellularized Wharton's Jelly Matrix for Regenerative Medicine and Cancer Application
This presentation is not available, by agreement with the author.
Pre-Clinical Development of MSC Therapies
-
CT
This presentation is not available, by agreement with the author.
Pre-Clinical Development of MSC Therapies
This presentation is not available, by agreement with the author.
Preclinical Studies of Cord Blood Monocytes and Monocyte-Derived Products
-
CT
This presentation is not available, by agreement with the author.
Preclinical Studies of Cord Blood Monocytes and Monocyte-Derived Products
This presentation is not available, by agreement with the author.
Translating Cord Blood-Derived Virus-Specific T-Cells
-
CT
This presentation is not available, by agreement with the author.
Translating Cord Blood-Derived Virus-Specific T-Cells
This presentation is not available, by agreement with the author.
One Platform, Multiple Cell Types
-
CT
This presentation is not available, by agreement with the author.
One Platform, Multiple Cell Types
This presentation is not available, by agreement with the author.
Cord Blood as Source Material for Novel iPSC -Derived Immunotherapeutics
-
CT
This presentation is not available, by agreement with the author.
Cord Blood as Source Material for Novel iPSC -Derived Immunotherapeutics
This presentation is not available, by agreement with the author.
Safety and Feasibility of Adjunct Autologous Cord Blood Cell Therapy During the Norwood Heart Operation for Neonates with Hypoplastic Left Heart Syndrome - First-in-Human Trials Results
-
CT
This presentation is not available, by agreement with the author.
Safety and Feasibility of Adjunct Autologous Cord Blood Cell Therapy During the Norwood Heart Operation for Neonates with Hypoplastic Left Heart Syndrome - First-in-Human Trials Results
This presentation is not available, by agreement with the author.
Generation of Multiple Cord Blood-Derived Immune Effector Cell Products from a Single Platform
-
CT
This presentation is not available, by agreement with the author.
Generation of Multiple Cord Blood-Derived Immune Effector Cell Products from a Single Platform
This presentation is not available, by agreement with the author.
Development of CAR-NK Cell Therapy for Hematologic Malignancies
-
CT
This presentation is not available, by agreement with the author.
Development of CAR-NK Cell Therapy for Hematologic Malignancies
This presentation is not available, by agreement with the author.
No items found.